Sunday, December 10, 2023
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO North America > News > J&J names consumer health business Kenvue ahead of spin-off

J&J names consumer health business Kenvue ahead of spin-off

in News
Johnson & johnson to end global sales of talc-based baby powder
Share on LinkedinShare on WhatsApp

Johnson & Johnson named its consumer business Kenvue on Wednesday, moving ahead with the company’s shake-up.

The conglomerate’s unit has faced thousands of lawsuits alleging talc products contained asbestos and were linked to mesothelioma and ovarian cancer in women.

The New Jersey based company has denied any allegations.

“Today’s announcement is another milestone for the consumer health business. Kenvue is poised to thrive as a standalone company with a leading portfolio of brands consumers love and trust. I’m confident in this team and excited to see what the future holds,” Johnson & Johnson CEO Joaquin Duato said.

The business owns Band-Aid, Tylenol, Listerine and Neutrogena among other brands and generated revenue of $14.6 billion in 2021.

The spin-off will be the biggest shake-up in the healthcare conglomerate’s 135-year history.

Kenvue (pronounced ken·view), is a combination of “ken” and English word meaning knowledge, and “vue,” referencing sight. According to the company Kenvue “will deliver meaningful, personal health solutions”.

Usage of the new company logo and corporate brand identity will be effective upon completion of the planned separation, which Johnson & Johnson last year said will be completed by November 2023.

Tags: Joaquin DuatoJohnson & JohnsonKenvue

Related Posts

Us set to approve dna-editing treatment for sickle cell patients
Innovation

US set to approve DNA-editing treatment for sickle cell patients

Lululemon stock falls after holiday guidance
Business

Lululemon stock falls after holiday guidance

Us mortgage rate reaches lowest level since august
Industry

US mortgage rate reaches lowest level since August

Levi strauss taps michelle gass as new ceo
Management & Leadership

Levi Strauss taps Michelle Gass as new CEO

Us mortgage refinance demand surges 14%
Industry

US mortgage refinance demand surges 14%

Us consumers purchased one million evs in 2023
Industry

US consumers purchased one million EVs in 2023

Mcdonald’s aims to add 9,000 new locations by 2027
Business

McDonald’s aims to add 9,000 new locations by 2027

Sag-aftra ratifies deal with amptp
Industry

SAG-AFTRA ratifies deal with AMPTP

Stellantis to relaunch fiat 500e ev in us market
Business

Stellantis to relaunch Fiat 500e EV in US market

Wells fargo cautions on high fourth quarter severance fees
Management & Leadership

Wells Fargo cautions on high fourth quarter severance fees

No Result
View All Result

Recent Posts

  • Airline industry predicts record travel year for 2024
  • Palm tree recycling could pose as plywood alternative
  • Meta makes encrypted messaging the default on Facebook
  • Shoplifting crime lags far behind retailers’ estimates
  • US set to approve DNA-editing treatment for sickle cell patients

Recent Comments

  • CEO North America, August - September 2023 - CEO North America on Interviews – CEO North America, October – November 2022
  • CEO North America, August - September 2023 - CEO North America on CEO North America, December 2022 – January 2023
  • CEO North America, August - September 2023 - CEO North America on Why Tech Companies Are Moving to Texas and Florida
  • CEO North America, August - September 2023 - CEO North America on CEO North America, February 2023 – March 2023
  • Lab-Grown Milk Has Huge Potential to Disrupt Dairy – Simply Commodities on The dairy industry is in trouble

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Editorials –
stuart.james@ceo-na.com

Advertising –
advertising@ceo-na.com

NEW YORK

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

HOUSTON

1201 Fannin St.
Suite 262
Houston, TX
77002
USA

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Editorials –
stuart.james@ceo-na.com

Advertising –
advertising@ceo-na.com

NEW YORK

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

HOUSTON

1201 Fannin St.
Suite 262
Houston, TX
77002
USA

CEO North America © 2022 - Sitemap

No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Warning: array_sum() expects parameter 1 to be array, null given in /home/ceonacom/public_html/wp-content/plugins/jnews-social-share/class.jnews-social-background-process.php on line 112